British Heart Foundation
Clinical Study Grants, for clinical trials and observational studies of specific patient groups, usually costing more than £300,000 or lasting more than 3 years.
- Interventional clinical trials: trials of specific interventions or pathways of care for the prevention, diagnosis and treatment of cardiovascular disease. Interventions include drugs, surgery, devices, psychological, physical and educational interventions.
- Observational studies of specific patient groups that are hypothesis led and address a defined clinical question(s) over a fixed timescale (up to 5 years). The population of interest should be a patient population, who will usually be recruited within the NHS. The study should have a predefined outcome(s) that will lead to changes in clinical management directly or will inform the development of a clinical trial to test an intervention.
- Clinical studies can include a mechanistic evaluation, either as a sub-study within a clinical trial or as part of an observational study.
- The Clinical Study Grant can also support pilot/feasibility studies and follow-on studies of interventional trials that cost less than £300,000 and are of shorter duration than 3 years. Please contact the BHF office to discuss applications for these types of study.
21/511 Health Technology Assessment Programme Researcher-led (primary research)
The Health Technology Assessment (HTA) Programme is part of the National Institute for Health Research (NIHR). The secretariat function of the Programme is managed by the NIHR Evaluation Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton under a contract with the Department of Health and Social Care.
The NIHR programmes currently have the following highlight notice open:
Brain Tumours. This highlight notice indicates the continuing interest of NIHR in receiving research proposals in this area, and it encourages collaborative applications that demonstrate how they build on recent initiatives and investment in the area made by the NIHR, the MRC and other research funders. Deadline: 13:00 on 01 September 2021
Invention for Innovation – Challenge Awards Call 12
The NIHR Invention for Innovation (i4i) programme invites proposals to Call 12 of its Challenge Awards on Real World Implementation.
The Challenge Awards will fund investigations of medtech innovations in healthcare settings. The aim is to shorten the evidence gap between the safety/efficacy typical of a newly or nearly CE marked technology and what is required for decisions by commissioners and regulators. At the same time, this will de-risk the product for follow-on investment. Please note that ‘nearly’ CE marked technologies refers to technologies that are currently under Notified Body assessment, whereby all of the mandatory testing has been completed.
The deadline for this call is on 10 June 2021 (1pm BST).
Invention for Innovation – Product Development Awards Call 22
The NIHR Invention for Innovation (i4i) programme invites proposals to Call 22 of its researcher-led Product Development Awards (PDA).
i4i PDA calls support translational research and development of medical devices, in vitro diagnostics and high-impact patient-focused digital health technologies for ultimate NHS use. The research proposals may address any disease or health area, provided there is a clear unmet clinical need. There is no upper funding limit for Product Development Awards, but costs must be fully justified.
Key eligibility criteria:
- Projects can be led by small-to-medium-sized enterprises (SME), NHS providers or higher education institutions (HEIs).
- Projects must be collaborative between any two of the eligible types of organisation.
- Projects can last a minimum of 24 months and a maximum of 36 months.
- The lead organisation must be registered in England.
The deadline for this call is on 09 June 2021 (1pm BST).
EME 21/506 – Efficacy and Mechanism Evaluation Programme – Researcher-led
Call for research proposals (21/506 Researcher-led)
Closing date: 1pm, 10 August 2021 (two stage – Stage 1 to Stage 2)
Stage 1 applications submitted to the Researcher Led call close on the 10 August 2021 assessed as in remit and competitive will be considered for shortlisting at the EME Funding Committee meeting in October 2021.